A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can ...

RAP-219 is a clinical-stage AMPA receptor negative allosteric modulator, designed to treat focal epilepsy and other CNS disorders. What were the results of the PET and MAD-2 trials for RAP-219?

Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy ... TARPγ8 associated AMPA receptors to significantly enhance ...

A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can develop following traumatic brain injury. Led by researchers at ...

Although scientists can learn a lot from cell culture and animal models, they cannot truly substitute for all parts of the ...

To understand how SynGAP's structure regulates synapses, the scientists analyzed synapses more closely to find that SynGAP protein competed with the binding of AMPA receptor/TARP complexes ...

Inhibition of AMPA receptor endocytosis could help treat addiction to heroin. Van den Oever et al. have used a rat model to demonstrate that the link between re-exposure to preconditioned stimuli ...

AMPA receptors are present throughout the brain ... as a potentially differentiated treatment for patients with focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania.

Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy ... evidence of selectively targeting TARPγ8 associated AMPA receptors ...

A Phase 2a proof-of-concept trial is currently underway to evaluate RAP-219 in patients with refractory focal epilepsy, with topline results expected in mid-2025. RAP-219 is a clinical-stage AMPA ...